Hainan Shuangcheng Pharmaceut (002693) - Total Assets

Latest as of September 2025: CN¥797.77 Million CNY ≈ $116.74 Million USD

Based on the latest financial reports, Hainan Shuangcheng Pharmaceut (002693) holds total assets worth CN¥797.77 Million CNY (≈ $116.74 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Hainan Shuangcheng Pharmaceut (002693) net assets for net asset value and shareholders' equity analysis.

Hainan Shuangcheng Pharmaceut - Total Assets Trend (2009–2024)

This chart illustrates how Hainan Shuangcheng Pharmaceut's total assets have evolved over time, based on quarterly financial data.

Hainan Shuangcheng Pharmaceut - Asset Composition Analysis

Current Asset Composition (December 2024)

Hainan Shuangcheng Pharmaceut's total assets of CN¥797.77 Million consist of 19.9% current assets and 80.1% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 5.8%
Accounts Receivable CN¥26.56 Million 3.4%
Inventory CN¥80.54 Million 10.3%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥175.02 Million 22.3%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2009–2024)

This chart illustrates how Hainan Shuangcheng Pharmaceut's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Hainan Shuangcheng Pharmaceut market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Hainan Shuangcheng Pharmaceut's current assets represent 19.9% of total assets in 2024, a decrease from 32.5% in 2009.
  • Cash Position: Cash and equivalents constituted 5.8% of total assets in 2024, down from 10.2% in 2009.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 12.0% in 2009.
  • Asset Diversification: The largest asset category is intangible assets at 22.3% of total assets.

Hainan Shuangcheng Pharmaceut Competitors by Total Assets

Key competitors of Hainan Shuangcheng Pharmaceut based on total assets are shown below.

Company Country Total Assets
Changchun High & New Technology Industries Group Inc
SHE:000661
China CN¥31.46 Billion
Yuhan Corp.
KO:000100
Korea ₩3.05 Trillion
Tasly Pharmaceutical Group Co Ltd
SHG:600535
China CN¥15.34 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥15.32 Billion
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
China CN¥10.96 Billion
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
China CN¥1.54 Billion
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
China CN¥6.74 Billion
Cronos Group Inc
TO:CRON
Canada CA$1.18 Billion

Hainan Shuangcheng Pharmaceut - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.86 1.00 1.53
Quick Ratio 0.45 0.49 1.12
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥-28.37 Million CN¥-675.01K CN¥68.09 Million

Hainan Shuangcheng Pharmaceut - Advanced Valuation Insights

This section examines the relationship between Hainan Shuangcheng Pharmaceut's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 8.15
Latest Market Cap to Assets Ratio 0.66
Asset Growth Rate (YoY) -2.4%
Total Assets CN¥783.87 Million
Market Capitalization $520.65 Million USD

Valuation Analysis

Below Book Valuation: The market values Hainan Shuangcheng Pharmaceut's assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.

Slight Asset Contraction: Hainan Shuangcheng Pharmaceut's assets decreased by 2.4% over the past year, which may reflect streamlining or optimization of resources.

Annual Total Assets for Hainan Shuangcheng Pharmaceut (2009–2024)

The table below shows the annual total assets of Hainan Shuangcheng Pharmaceut from 2009 to 2024.

Year Total Assets Change
2024-12-31 CN¥783.87 Million
≈ $114.70 Million
-2.41%
2023-12-31 CN¥803.25 Million
≈ $117.54 Million
-11.83%
2022-12-31 CN¥911.02 Million
≈ $133.31 Million
+6.61%
2021-12-31 CN¥854.56 Million
≈ $125.05 Million
-5.85%
2020-12-31 CN¥907.68 Million
≈ $132.82 Million
-4.55%
2019-12-31 CN¥950.98 Million
≈ $139.16 Million
-15.11%
2018-12-31 CN¥1.12 Billion
≈ $163.93 Million
-18.65%
2017-12-31 CN¥1.38 Billion
≈ $201.52 Million
+18.15%
2016-12-31 CN¥1.17 Billion
≈ $170.55 Million
-24.81%
2015-12-31 CN¥1.55 Billion
≈ $226.84 Million
+64.29%
2014-12-31 CN¥943.54 Million
≈ $138.07 Million
+2.89%
2013-12-31 CN¥917.04 Million
≈ $134.19 Million
+3.43%
2012-12-31 CN¥886.65 Million
≈ $129.74 Million
+257.44%
2011-12-31 CN¥248.06 Million
≈ $36.30 Million
-1.85%
2010-12-31 CN¥252.73 Million
≈ $36.98 Million
+158.28%
2009-12-31 CN¥97.85 Million
≈ $14.32 Million
--

About Hainan Shuangcheng Pharmaceut

SHE:002693 China Drug Manufacturers - Specialty & Generic
Market Cap
$520.65 Million
CN¥3.56 Billion CNY
Market Cap Rank
#12331 Global
#3822 in China
Share Price
CN¥8.58
Change (1 day)
-0.35%
52-Week Range
CN¥6.52 - CN¥9.16
All Time High
CN¥38.37
About

Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmace… Read more